Mounjaro®
Starting from £179.99/mo
Start journey Learn moreEach single dose of Mounjaro (tirzepatide) is 0.5 ml, regardless of which strength you are using. The 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths all deliver the same 0.5 ml injection volume; what changes between strengths is the concentration of tirzepatide dissolved in that fixed volume, not the amount of liquid you inject. Mounjaro is a prescription-only medicine, so the dose you use at any point is determined by a prescriber following clinical assessment, not chosen by you independently. The KwikPen is pre-set — there is no dial to turn or volume to measure.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes. The 0.5 ml dose volume is fixed across the entire Mounjaro range. A question our prescribers hear most weeks is whether the liquid amount goes up as the dose escalates, and the answer is no. Eli Lilly designed the KwikPen so that the physical experience of injecting stays consistent from the 2.5 mg starter pen right through to the 15 mg maintenance pen. What varies is the concentration: a 15 mg pen contains a much higher amount of tirzepatide dissolved into each 0.5 ml than a 2.5 mg pen does.
This matters practically. When you move up to a higher-strength pen, you will not notice a difference in how much liquid enters the injection site. Some people expect the injection to feel heavier or to take longer at stronger doses; it does not. The fixed-volume design also means that any redness, swelling or stinging at the site is unlikely to be related to a larger fluid volume pushing through.
For full detail on how the 5 mg pen compares in terms of concentration, the volume and concentration of the 5 mg strength is covered separately.
The Mounjaro KwikPen is a pre-filled, pre-set auto-injector. There is no plunger to push manually and no volume marker to line up. You press the pen against the injection site, press the button, and the device delivers exactly 0.5 ml, and if you want to understand how many ml make up one dose of Mounjaro, that is explained in full on its own page. Once that dose is complete, an indicator window on the pen changes to confirm delivery.
Each pen is designed for four weekly injections, so it contains 2 ml of solution in total (four times 0.5 ml). After the fourth use the pen is empty and should be disposed of in a sharps container as described in the Patient Information Leaflet. You do not need to calculate how much is left; the pen tracks use mechanically.
The KwikPen can be injected into the abdomen, the front of the thigh or the upper arm. Rotating sites within and across these areas from one week to the next is recommended to reduce localised reactions. For technique questions, the Mounjaro overview page covers preparation and injection steps in more detail.
The 0.5 ml volume stays the same, so the physical feel of the injection itself is largely identical across strengths. The 2.5 mg pen is the lowest concentration, but it is not a smaller injection. Its purpose is to give the body time to adjust to tirzepatide before the dose escalates; starting low reduces the likelihood of nausea and other gastrointestinal side effects in the early weeks.
This is worth knowing if you are moving from the 2.5 mg starting strength to the 5 mg pen for the first time. The liquid amount does not change, and a closer look at how many ml are in the 5 mg Mounjaro pen can help set expectations before you make that switch. If you notice a difference in how you feel after injecting a stronger pen, that is the pharmacological effect of higher tirzepatide exposure, not a larger bolus of fluid.
The NHS tirzepatide patient information at nhs.uk/medicines/tirzepatide sets out what to expect at each stage of treatment, including side effects that are common during dose escalation. Your prescriber and the leaflet packaged with your pen are the right sources for any questions about when to increase, pause or change your dose.
Occasionally people notice a small amount of liquid on the skin after removing the pen. A tiny residual droplet at the needle tip is normal and does not mean the dose was incomplete; the pen is designed so that the full 0.5 ml is delivered before the needle retracts. Holding the pen in place for around 10 seconds after the button click, then slowly removing it, gives the mechanism time to complete the dose.
If you are consistently unsure whether doses are going in correctly, or if you notice that the dose indicator is not moving as expected, that is a question for your prescriber rather than something to self-troubleshoot. Timing, site rotation and technique can all affect comfort and confidence with subcutaneous injections, and clinical guidance specific to your situation is always the better route than forum advice.
Private treatment costs vary by provider and dose. If you are weighing up the overall cost of a Mounjaro course, the Mounjaro pricing page explains what is typically included and what to look out for. Mounjaro is a prescription-only medicine; clinical assessment by a GPhC-registered Independent Prescriber is required before treatment can start or continue.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.